Fox Chase Names Anthony J. Olszanski Director of Clinical Pharmacology for Phase I Clinical Trial Program
PHILADELPHIA (November 9, 2009) – Anthony J. Olszanski, RPh, MD - Director, Early Clinical Drug Development, Clinical Trials; Co-Director, Melanoma Program, has joined Fox Chase Cancer Center as director of clinical pharmacology for the phase I clinical trial program. At Fox Chase, Olszanski will provide care to patients who no longer respond to standard chemotherapy or for which few options exist. In addition, he will treat patients with gastrointestinal malignancies and melanoma. His main research interest focuses on early drug development, in an effort to discover new, more effective therapies for cancer patients.
“When you step through the doors at Fox Chase, it is obvious that focusing on the patient is the top priority,” says Olszanski. “I am proud to be a member of this caring community, where oncology research and science is tailored and personalized for each patient.”
Olszanski comes to Fox Chase from Pfizer Oncology. He completed a fellowship in clinical pharmacology/toxicology and hematology/oncology at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire.
“During my hematology/oncology and clinical pharmacology fellowships, I spent a great deal of time in early clinical development, with a goal of finding new effective therapies for patients with cancer,” says Olszanski. “I honed my knowledge of drug discovery by spending five years in the pharmaceutical industry where I led multiple programs aimed at treating patients with cancers that didn’t respond to traditional chemotherapy.”
Olszanski earned his MD from the University of Medicine and Dentistry of New Jersey in Newark, New Jersey. He is certified in medical oncology, clinical pharmacology and internal medicine
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.